Over the last 30 years, David has managed clinical and engineering teams at large and small medical device companies including Intermedics, Guidant, Boston Scientific St. Jude and Endosense. He has successfully led programs to clinically validate and commercialize novel technologies that improve quality of life and overcome debilitating illness. His command of the US regulatory environment led to the successful approval and adoption of a market leading contact force sensing ablation device at Endosense that was profitably acquired by St. Jude Medical, now Abbott. David holds a degree in Engineering Sciences and Biomedical Engineering from the University of Michigan. Before joining industry, he devoted 7 years to scientific research at Newark Beth Israel Medical Center in cardiothoracic surgery and electrophysiology. David joined GTX Medical in November of 2019.